Scalper1 News
In a recurring theme for big pharma this earnings season, Pfizer’s (PFE) Q1 sales missed Wall Street’s expectations, but the company controlled expenses well enough to beat on the bottom line. Its stock slid more than 2% on the stock market today. Pfizer’s Q1 earnings totaled 57 cents a share, up 12% from the year-earlier quarter and beating analysts’ consensus by 2 cents. Sales declined 9% to $11.35 billion, missing consensus by about $750 Scalper1 News
Scalper1 News